“Everyone seems to agree: Drug prices are too damn high.”
So begins a post from Rachel Sachs, Darius Lakdawalla, and me at the Health Affairs Blog on the complicated interplay between value-based pricing and Medicaid’s best-price rule. What is the best-price rule? Does it really impede the adoption of value-based pricing? If so, what can be done about it? To keep federal spending in check, […]